EWA
SRPT icon

EP Wealth Advisors’s Sarepta Therapeutics SRPT Stock Holding History

EP Wealth Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,883
Closed -$213K – 1591
2025
Q4 		$213K Buy
+9,883
New +$208K ﹤0.01% 1354
2025
Q2 		– Sell
-5,042
Closed -$322K – 1470
2025
Q1 		$322K Buy
5,042
+54
+1% +$5.68K ﹤0.01% 881
2024
Q4 		$606K Buy
4,988
+105
+2% +$12.9K ﹤0.01% 636
2024
Q3 		$610K Sell
4,883
-16
-0.3% -$2.21K 0.01% 634
2024
Q2 		$774K Buy
4,899
+103
+2% +$13.2K 0.01% 435
2024
Q1 		$621K Hold
4,796
– – 0.01% 472
2023
Q4 		$462K Buy
+4,796
New +$460K 0.01% 507
2023
Q3 		– Sell
-19,327
Closed -$530K – 775
2023
Q2 		$530K Buy
+19,327
New +$2.49M 0.01% 454

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EP Wealth Advisors's SRPT Position: Q1 2026 in Review

EP Wealth Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 9,883 shares — an estimated $213K sold.

EP Wealth Advisors first reported a position in SRPT in Q2 2023 and held it in 8 quarters. The position peaked at $774K in Q2 2024. 344 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • EP Wealth Advisors reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
  • EP Wealth Advisors sold 9,883 Sarepta Therapeutics shares in Q1 2026, an estimated $213K.
  • EP Wealth Advisors first reported a position in Sarepta Therapeutics in Q2 2023 and held it in 8 quarters.
  • EP Wealth Advisors's Sarepta Therapeutics position peaked at $774K in Q2 2024.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on EP Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.